Introduction

Xenograft models have transformed preclinical oncology by providing in vivo systems that retain many biological and molecular features of human tumors. Yet, long-term use of these models introduces significant challenges in quality control, reproducibility, and biological fidelity. Over multiple passages, xenografts undergo evolutionary drift, stromal replacement, and selective pressures that alter their resemblance to the original patient tumor. Understanding and mitigating these variables is critical for ensuring reliable data generation and maintaining translational relevance.

Genetic Drift in Serial Passaging

One of the most pressing challenges in xenograft maintenance is genetic drift. During serial transplantation, subclonal populations adapt to the murine host environment, leading to altered mutational spectra, copy number variations, and transcriptomic changes. While early passages (P0–P3) typically preserve the architecture and heterogeneity of the original patient tumor, later passages often show evidence of clonal selection. This clonal dominance may artificially amplify drug response signatures that differ from the patient’s disease course. Researchers therefore prioritize the use of low-passage xenografts in both academic and pharmaceutical pipelines.

Stromal Replacement and Microenvironmental Shifts

Xenografts inherently replace human stromal components with murine counterparts over time. Fibroblasts, vascular networks, and extracellular matrix proteins originating from the host mouse gradually dominate the microenvironment. While this facilitates tumor engraftment and expansion, it also alters paracrine signaling and drug penetration profiles. Therapies targeting tumor–stroma interactions in humans may not behave identically in xenograft systems, particularly in late-passage tumors. This limitation has prompted parallel development of co-engraftment strategies using human stromal cells or engineered scaffolds.

Reproducibility and Standardization Issues

Variability in engraftment rates, growth kinetics, and host strain selection creates challenges in reproducibility across institutions. Even subtle differences in implantation site, mouse age, or housing conditions can alter tumor take rates and growth dynamics. Standardized protocols, strict passage tracking, and cross-validation studies are essential for harmonizing results. Cryopreservation of low-passage tumors for future use is one of the most effective quality control strategies, enabling reproducibility and consistency across projects.

Quality Control Practices

• Authentication of xenograft tissue using short tandem repeat (STR) profiling to prevent misidentification.
• Regular histopathological validation to ensure preservation of tumor architecture.
• Genomic sequencing across passages to track drift and clonal evolution.
• Implementation of quality metrics such as tumor doubling time, engraftment latency, and histological scoring.
• Cross-laboratory benchmarking using reference xenografts for inter-study comparability.

Future Directions

Emerging strategies aim to improve fidelity and reproducibility of xenograft systems. Organoid-to-xenograft pipelines provide frozen stocks of genetically validated patient-derived organoids that can be engrafted repeatedly, minimizing drift. Integration of single-cell sequencing allows researchers to monitor subclonal stability at unprecedented resolution. Moreover, the establishment of international biobanks and harmonized reporting standards will reduce variability and accelerate translational insights. As xenograft research expands, addressing quality control and genetic drift will remain fundamental to preserving the predictive power of these models.